Pinion Immunotherapeutics

Executive Summary

Pinion Immunotherapeutics is a private biotechnology company leveraging a proprietary AI-driven mRNA platform to develop novel immunotherapies for chronic viral infections and virus-driven cancers. Founded in 2021 and headquartered in Cambridge, Maryland, the company targets indications such as HPV-related precancer, acute myeloid leukemia (AML), Epstein-Barr virus (EBV), and herpes simplex virus (HSV). Its technology aims to activate CD8+ T cells while inducing virus-neutralizing antibodies, potentially achieving durable immune control. Pinion is currently in Phase 1/2 clinical development, with its lead program focused on HPV-related disease. The platform's versatility and AI-enabled design offer a competitive edge in addressing multiple high-need indications, though the company remains in early clinical stages with no approved products or disclosed financial backing yet.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 data readout for HPV immunotherapy lead program35% success
• Q4 2026IND filing for AML indication40% success
• TBDAnnouncement of strategic partnership or funding round50% success